Get the full Orakl Oncology company profile
Access contacts, investors, buying signals & more
Orakl Oncology has raised $34.0M in Series A funding. The Paris-based company pairs biology with clinical data, using a collection of patient tumor avatars to help oncology partners identify relevant targets and bring new drugs to patients faster.
Norrsken VC, Singular, Infravia Capital Partners, Serena, Bpifrance, Teampact Ventures, Plug and Play, Verve Ventures, Speedinvest and HCVC all participated in the round.
Can AI predict which cancer drugs will actually work? Orakl Oncology raises âŹ30 million to find out | EU-Startups Home France-Startups Can AI predict which cancer drugs will actually work? Orakl Oncology raises... France-Startups Funding Can AI predict which cancer drugs will actually work?
Orakl Oncology raises âŹ30 million to find out By David Cendon Garcia November 12, 2026 Share Facebook X WhatsApp Linkedin Orakl Oncology , a French TechBio company using AI and real patient biology to predict how cancer drugs will perform in clinical trials, today announced a âŹ30 million ($34 million) Series A. The round was co-led by Norrsken VC and Singular. It included new investors InfraVia Ca
Orakl Oncology
Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.
$34.4M Series a
today
Bluelinea
« Prendre soin de vos parents, quâils soient ĂągĂ©s et/ou en situation de handicap, Ă domicile comme en Ă©tablissement». Tel est lâobjectif principal de Bluelinea. Pour l'atteindre, notre Ă©quipe Ćuvre jour et nuit Ă cette mission, portĂ©e par la vĂ©ritable promesse aux familles que l'on souhaite tenir au quotidien. Par sa plateforme dâĂ©coute 24h24 et son bouquet de services connectĂ©s BlueHomeCareÂź, la sociĂ©tĂ© se positionne comme le conseiller des familles Ă domicile en permettant de les accompagner jour et nuit. Aujourdâhui, plus de 25.000 particuliers font ainsi confiance aux offres innovantes de Bluelinea et plus de 700 Ă©tablissements de santĂ© sont Ă©quipĂ©s de l'une ou l'autre de nos solutions. L'adaptation du logement - domicile ou institution - est Ă©galement un axe de dĂ©veloppement important du Groupe, car dĂ©terminant dans la perspective de crĂ©er des conditions favorables au maintien Ă domicile des personnes ĂągĂ©es et handicapĂ©es. Du Pack Jeune Senior pour bien commencer sa retraite jusquâĂ lâEHPAD connectĂ©, des offres de Bouton dâAppel 24h24 au bracelet dâautonomie pour personnes atteintes de la maladie dâAlzheimer, Bluelinea innove en proposant des solutions adaptĂ©es Ă chaque situation de la vie. Cette dĂ©marche permet ainsi de prolonger lâespĂ©rance de vie en bonne santĂ© de chacun. 3 gammes de produits : Senior ConnectĂ© : Bouton d'Appel 24h24, Sara 24h24, BluePhone, BlueGard (Alzheimer), DĂ©tection de Chutes, Pack Jeune Senior (coaching et tracker d'activitĂ©). Domicile ConnectĂ© : Domotique, BlueHub (reconnaissance vocale Siri), Gestion d'environnement Ă distance, Motorisation d'Ouvrants HĂŽpital & EHPAD ConnectĂ© : SERENEA, Appel InfirmiĂšre, TĂ©lĂ©phonie, BlueTag (SĂ©curisation des bĂ©bĂ©s en maternitĂ©), BlueTag Senior (Alzheimer et dĂ©sorientation), BlueGard (Alzheimer et dĂ©sorientation) Plus dâinformations : www.bluelinea.com. Rejoignez-nous sur Twitter (@Bluelinea), Facebook (Bluelinea) et Youtube (Groupe Bluelinea).
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 |  NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Mount Thor, Inc. | Series a | $45.0M | today |
| 2 |  luminal | Series a | $25.0M | today |
| 3 |
$6.0M Unknown
4 days ago
| $7.2B |
| 2y ago |
| 3 |  Illumina United States | Unknown | $7.1B | 2y ago |
| 4 |  GRAIL United States | Unknown | $7.1B | 2y ago |
| 5 |  RemeGen Biosciences United States | Grant | $5.6B | 10mo ago |
 Tristar AI United States |
| Series a |
| $12.4M |
| today |
| 4 | Hatz AI United States | Series a | $24.0M | today |
| 5 |  SE3 Labs Germany | Series a | $30.0M | today |
Trusted by 200+ sales teams
Norrsken VC
VC FIRM
Singular
VC FIRM
Unlock 8 more investors and reach their contacts directly.
Start free trial
Kindo
Recently received
Qvyon Technologies
Recently received
Mount Thor, Inc.
Recently received
